Patricia Brafford

发表

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

G. Mills, M. Morgan, R. Mach, 2017, JCI insight.

Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

G. Mills, A. Weeraratna, G. Caponigro, 2015, Clinical Cancer Research.

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

D. Schadendorf, S. Ugurel, B. Weber, 2006, Pigment cell research.

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

Keith T Flaherty, Meenhard Herlyn, K. Flaherty, 2006, Molecular Cancer Therapeutics.

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Sydney M. Shaffer, A. Raj, M. Herlyn, 2017, Nature.

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

Alexander Roesch, Devraj Basu, Meenhard Herlyn, 2010, Cell.

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer

G. Mills, Yiling Lu, Gao Zhang, 2015, Clinical Cancer Research.

A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells

G. Mills, P. Gimotty, M. Herlyn, 2022, Neuro-oncology.

PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas

M. Herlyn, K. Smalley, N. Haass, 2010, Pigment cell & melanoma research.

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.

Chelsea C Pinnix, Min Xiao, Meenhard Herlyn, 2006, Cancer research.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Yiling Lu, Lauren E Haydu, Gordon B Mills, 2017, Cell reports.

Selective evolutionary pressure from the tissue microenvironment drives tumor progression.

Meenhard Herlyn, M. Herlyn, K. Smalley, 2005, Seminars in cancer biology.

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.

G. Mills, A. Weeraratna, K. Flaherty, 2016, The Journal of clinical investigation.

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

J. Becker, K. Kaestner, D. Weiner, 2021, Nature communications.

Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility.

Stephen M. Douglass, A. Raj, A. Weeraratna, 2018, Cancer discovery.

Epigenetic state determines inflammatory sensing in neuroblastoma

Liron D. Grossmann, Yasin Uzun, C. Dang, 2021, Proceedings of the National Academy of Sciences.

MCU controls melanoma progression through a redox‐controlled phenotype switch

M. Herlyn, S. Jakobs, C. Lenz, 2022, EMBO reports.

Distinct histone modifications denote early stress-induced drug tolerance in cancer

G. Mills, K. Flaherty, M. Herlyn, 2017, Oncotarget.

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

M. Herlyn, K. Nathanson, M. Xiao, 2016, Oncotarget.

Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells

J. Orange, C. Dang, D. Felsher, 2022, Cancer research communications.

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Nancy R. Zhang, D. Elder, C. Shields, 2017, Cell reports.

Mutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma

M. Herlyn, Hong Yu, Xiaowei Xu, 2007 .

Active Notch1 confers a transformed phenotype to primary human melanocytes.

P. Pollock, A. Weeraratna, M. Herlyn, 2009, Cancer research.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

G. Mills, K. Flaherty, Dennie T. Frederick, 2018, Clinical Cancer Research.

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

M. Herlyn, Hong Yu, Xiaowei Xu, 2007, Cancer research.

Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.

Eric Brown, Meenhard Herlyn, M. Herlyn, 2005, The American journal of pathology.

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma

M. Herlyn, Rugang Zhang, K. Aird, 2016, Molecular Cancer Research.

Genetic and Genomic Characterization of 462 Melanoma Patient-Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Derived Xenografts, Tumor Biopsies, and Cell Lines.

Dennie T. Frederick, M. Herlyn, J. Wargo, 2022 .

A Comprehensive Patient-Derived Xenograft Collection A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Representing the Heterogeneity of Melanoma.

Dennie T. Frederick, G. Caponigro, M. Herlyn, 2022 .

Protein Signatures of NK Cell–Mediated Melanoma Killing Predict Response to Immunotherapies

M. Herlyn, P. Rehling, V. Helms, 2021, Cancer Research.

Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance

G. Mills, J Zhang, K. Flaherty, 2021, Cancer Research.

Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma

M. Herlyn, M. Xiao, M. Gstaiger, 2021, Oncogene.

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

K. Kaestner, H. Dweep, M. Herlyn, 2021, Nature Communications.

ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.

G. Mills, A. Weeraratna, M. Herlyn, 2017, Cancer research.